Immunotherapies: Exploiting the Immune System for Cancer Treatment

被引：111

作者：

Koury, Jeffrey ^{[1
]}

Lucero, Mariana ^{[1
]}

Cato, Caleb ^{[1
]}

Chang, Lawrence ^{[1
]}

Geiger, Joseph ^{[1
]}

Henry, Denise ^{[1
]}

Hernandez, Jennifer ^{[1
]}

Hung, Fion ^{[1
]}

Kaur, Preet ^{[1
]}

Teskey, Garrett ^{[1
]}

Tran, Andrew ^{[1
]}

机构：

[1] Western Univ Hlth Sci, Grad Coll Biomed Sci, Pomona, CA 91766 USA

来源：

JOURNAL OF IMMUNOLOGY RESEARCH | 2018年 / 2018卷

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; T-CELL-ACTIVATION; HEPATOCYTE GROWTH-FACTOR; RECOMBINANT INTERLEUKIN-2 THERAPY; METASTATIC MELANOMA PATIENTS; PURIFIED HUMAN INTERLEUKIN-2; ANTIBODY FUSION MOLECULES; TERM-FOLLOW-UP; BISPECIFIC ANTIBODIES; C-MET;

D O I：

10.1155/2018/9585614

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers.

引用

页数：16

共 131 条

[1] Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy [J].

Acheampong, Desmond O. ;

Adokoh, Christian K. ;

Ampomah, Paulina ;

Agyirifo, Daniel S. ;

Dadzie, Isaac ;

Ackah, Francis A. ;

Asiamah, Ernest A. .

PROTEIN AND PEPTIDE LETTERS, 2017, 24 (05) :456-465

[2] A mini-review of c-Met as a potential therapeutic target in melanoma [J].

Al-U'datt, Doa'a G. F. ;

Al-Husein, Belal A. A. ;

Qasaimeh, Ghazi Raji .

BIOMEDICINE & PHARMACOTHERAPY, 2017, 88 :194-202

[3]

[Anonymous], 2017, CANC DISCOVOVERY

[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[5] 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond [J].

Ascierto, Paolo A. ;

Marincola, Francesco M. .

EBIOMEDICINE, 2015, 2 (02) :92-+

[6] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[7] Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].

Baeuerle, Patrick A. ;

Reinhardt, Carsten .

CANCER RESEARCH, 2009, 69 (12) :4941-4944

[8] The role of HGF/c-MET signaling pathway in lymphoma [J].

Bao Quoc Lam ;

Dai, Lu ;

Qin, Zhiqiang .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 :1-8

[9]

BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69

[10] Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Itzhaki, Orit ;

Treves, Avraham J. ;

Zippel, Douglas B. ;

Levy, Daphna ;

Kubi, Adva ;

Shoshani, Noa ;

Zikich, Dragoslav ;

Ohayon, Yaara ;

Ohayon, Daniel ;

Shalmon, Bruria ;

Markel, Gal ;

Yerushalmi, Ronit ;

Apter, Sara ;

Ben-Nun, Alon ;

Ben-Ami, Eytan ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2013, 19 (17) :4792-4800

← 1 2 3 4 5 6 7 8 9 10 →